New Blood Test Shows Promise in Catching One of the Deadliest Cancers Early
Identifying pancreatic cancer earlier in patients could give doctors more time to act before it becomes harder to treat.
A groundbreaking blood test has shown great promise in early detection of pancreatic cancer, potentially revolutionizing both diagnostics and treatment options. Researchers collaborated from the U.S. and international regions, including China, Korea, and Japan, to develop the test, which combines three biological markers and artificial intelligence to estimate a patient's risk of having pancreatic cancer.
Pancreatic cancer is notoriously difficult to detect early due to its deep location within the body and often lack of symptoms until advanced stages. The test, called PANXEON, achieved an impressive 87% accuracy in identifying patients with stage 1 and 2 cancer across nearly 1,800 participants from various countries. With a low false-positive rate, PANXEON detected high-grade dysplasia, an advanced precancerous lesion, in about 64% of cases.
Experts believe this test could shift the timing of diagnosis, potentially improving survival rates by enabling more patients to undergo curative-intent treatments. However, further extensive testing is required to determine its effectiveness and potential impact on patient outcomes.
Written by urgent.news from Newsweek's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
